ABSTRACT

Female nurses die by suicide at approximately twice the rate of the general female population. A parallel literature documents that suicide attempts and deaths among people assigned female at birth (AFAB) concentrate during menstrual cycle phases of low estradiol and low progesterone, and that premenstrual dysphoric disorder (PMDD) confers approximately sevenfold elevated odds of suicide attempt and a 1.92-fold hazard of suicide death. These findings have never been studied in the same population. This manuscript establishes that intersection as a formally documented research gap, generates testable hypotheses, extends the analysis to transgender men and AFAB nonbinary individuals in healthcare, introduces a compounding neurobiological deficit model linking cholesterol substrate availability and thyroid function to the primary hormonal mechanism, and develops legal and policy frameworks governing employer and provider obligations to a workforce carrying documented, modifiable suicide risk.

Registered nurses constitute the largest professional segment of the U.S. healthcare workforce and bear a disproportionate burden of occupational psychiatric morbidity, including post-traumatic stress disorder, premenstrual dysphoric disorder (PMDD), and suicidal ideation. Despite decades of evidence linking shift work, hormonal dysregulation, and institutional moral suppression to measurable neurobiological harm, this workforce receives no standardized occupational mental health surveillance and faces diagnostic delays averaging more than a decade for PMDD alone.

This analysis establishes the aggregate economic burden of PMDD-associated occupational harm and suicide in the U.S. registered nurse workforce, maps five convergent neurobiological pathways to a common mechanistic endpoint, and positions these findings within an institutional accountability and failure-to-rescue framework. A structured literature synthesis drew on peer-reviewed sources across psychiatry, neuroendocrinology, occupational health, and health economics, supplemented by federal workforce surveillance data from the Health Resources and Services Administration, the National Council of State Boards of Nursing, and the Bureau of Labor Statistics. Economic burden calculations applied published per-person cost estimates to a nursing-specific prevalence model. The Continuity Risk Framework (CRF), Clinical Moral Disengagement Scaffolding (CMDS), and Comprehensive Occupational Violence and Extraction Framework (COVE-F) provided the analytic architecture for institutional and systemic attribution.

An estimated 23% of ICU nurses and 18% of general medical-surgical nurses meet full diagnostic criteria for PTSD (Mealer et al., 2009), with COVID-era meta-analytic pooled prevalence reaching 29.1% across nursing populations globally (Hernandez-Bojorge et al., 2024), producing an aggregate annual economic burden of approximately $14.0 billion. PMDD, affecting 3% to 8% of women of reproductive age and an estimated subset of AFAB individuals, is misdiagnosed at high rates as bipolar disorder or treatment-resistant depression. Five neurobiological pathways converge on mitochondrial neurosteroid synthesis: PMDD-associated GABA-A receptor hypersensitivity, statin-mediated cholesterol reduction, hypothyroid StAR protein impairment, ACE-driven HPA axis dysregulation, and PTSD-related allopregnanolone depletion. Under conditions of occupational exposure -- shift work, sleep deprivation, sustained cortisol elevation, and institutional coercion -- these pathways produce compound allopregnanolone reduction and measurable increase in suicide risk.

The economic and clinical cost of this harm is preventable. Institutional accountability, diagnostic accuracy, and occupational surveillance structured within validated escalation frameworks offer a tractable intervention pathway.